Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Synthetic Cell Technology Could Benefit Vaccine Production, Venter Says

Executive Summary

J. Craig Venter's synthetic cell may dramatically speed up vaccine production, he told a Congressional committee

You may also be interested in...



Venter Targets Life Extension With New Genomic Research Company

The former Celera CEO has raised $70 million for a new organization that will use genomic, biochemical and microbiome data to find stem cell-based treatments for aging-related disorders.

WHO Closer To FDA Approval For Malaria Drug

FDA has been holding the world body to the same standards it uses for a regular drug review, resulting in many years of delay in bringing artesunate rectal suppositories to market - but the Anti-Infective Drugs Advisory Committee has given a partial endorsement.

First Cell-Derived Flu Vaccine Reaches Advisory Committee

Protein Sciences' seasonal influenza vaccine FluBlok has typical immunity data but some manufacturing issues.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS052287

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel